ecopipam has been researched along with Restless Legs Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Olubajo, T; Ondo, WG | 1 |
| Clemens, S; Dinkins, ML; Lallemand, P | 1 |
1 trial(s) available for ecopipam and Restless Legs Syndrome
| Article | Year |
|---|---|
Exploratory cross-over, trial of augmented RLS with the dopamine receptor 1/5 antagonist ecopipam D1/D5 antagonist ecopipam for augmented RLS.
Topics: Benzazepines; Cross-Over Studies; Dopamine Antagonists; Humans; Restless Legs Syndrome | 2022 |
1 other study(ies) available for ecopipam and Restless Legs Syndrome
| Article | Year |
|---|---|
Long-term treatment with dopamine D3 receptor agonists induces a behavioral switch that can be rescued by blocking the dopamine D1 receptor.
Topics: Animals; Benzazepines; Benzothiazoles; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Male; Mice, Inbred C57BL; Pain Threshold; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D3; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes | 2017 |